783 results on '"Schreiber, Stefan"'
Search Results
2. Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn’s Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study
3. Epidemiologische Daten und medizinische Versorgungssituation von Patienten mit chronischen Entzündungserkrankungen in Deutschland: Real-World-Evidenz zu Prävalenz, Erkrankungskombinationen, Versorgung
4. Amino acid auxotrophies in human gut bacteria are linked to higher microbiome diversity and long-term stability
5. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort
6. Trends in the epidemiology of Clostridioides difficile infection in Germany
7. Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s disease
8. Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial
9. Genome-wide association analysis reveals the associations of NPHP4, TYW1-AUTS2 and SEMA6D for Behçet's disease and HLA-B*46:01 for its intestinal involvement
10. Depression and fatigue six months post-COVID-19 disease are associated with overlapping symptom constellations: A prospective, multi-center, population-based cohort study
11. Effects of lifestyle and associated diseases on serum CC16 suggest complex interactions among metabolism, heart and lungs
12. Tryptophan degradation as a systems phenomenon in inflammation – an analysis across 13 chronic inflammatory diseases
13. Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
14. Serine metabolism is crucial for cGAS-STING signaling and viral defense control in the gut
15. Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study
16. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure
17. Mirikizumab bei Colitis ulcerosa
18. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
19. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment
20. Cohort profile: the Food Chain Plus (FoCus) cohort
21. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
22. Resilienz als Resonanzfähigkeit. Ein affekttheoretischer Blick auf ein psycho-sozio-archäologisches Forschungsfeld
23. Atmungstherapie an einem Universitätsklinikum: eine Evaluation des Tätigkeitsprofils
24. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
25. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics
26. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer
27. THU-254-YI Differential gene expression profiles of liver tissue, subcutaneous and visceral adipose tissue delineates severity of MASLD in heavily obese patients
28. Dynamic changes in extracellular vesicle-associated miRNAs elicited by ultrasound in inflammatory bowel disease patients
29. AMISELIMOD FOR THE TREATMENT OF ACTIVE ULCERATIVE COLITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
30. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials
31. Safety, tolerability, and pharmacokinetics of single‐ and multiple‐ascending doses of olamkicept: Results from randomized, placebo‐controlled, first‐in‐human phase I trials
32. Manifestation of an immunologic dysbalance in the otological and sinunasal area based on therapeutic damage in autoimmune diseases
33. Single-cell RNA sequencing of nasal mucosa for molecular and genetic analysis of chemosensory dysfunction in post-COVID patients
34. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme
35. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
36. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study
37. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
38. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus
39. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study
40. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
41. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
42. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease
43. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity
44. DNA methyltransferase 3A controls intestinal epithelial barrier function and regeneration in the colon
45. Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients
46. Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease
47. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
48. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
49. Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study.
50. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.